JPRN-jRCTs071190035
Recruiting
Phase 1
Evaluation of FDG-PET/CT for the disease control assessment in pulmonary Mycobacterium avium complex (MAC) infection and chronic pulmonary aspergillosis
Takazono Takahiro0 sites15 target enrollmentNovember 15, 2019
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Takazono Takahiro
- Enrollment
- 15
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(1\) Patients diagnosed with pulmonary Mycobacterium avium complex (MAC) infection based on American Thoracic Society / American Society of Infectious Diseases Guideline 2017, or patients diagnosed with chronic pulmonary aspergillosis (CPA) based on the European Society of Clinical Microbiology / European Society of Medical Mycology / European Respiratory Society 2017\.
- •(2\) Patients who have not been treated with antimicrobial agents against pulmonary MAC infection or CPA .
- •(3\) Patients who are older than 20 at the time of informed consent.
- •(4\) Patients with written informed consent after receiving sufficient information.
Exclusion Criteria
- •(1\) Diabetic patients with poor control (more than 200 mg/dL of fasting blood glucose level).
- •(2\) Patients with cystic fibrosis.
- •(3\) Patients with active respiratory infection except for pulmonary MAC infection or CPA.
- •(4\) Patients with pulmonary MAC infection and CPA.
- •(5\) Patients with lung cancer at the time of informed consent.
- •(6\) Women who are currently pregnant or may be pregnant.
- •(7\) Patient who are judged unsuitable for this study by the investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial SarcoidosisMyocardial sarcoidosisJPRN-UMIN000022996The Department of Cardiology, Nagoya University Graduate School of Medicine50
Completed
Not Applicable
sefulness of FDG-PET/CT examination as prediction of effect of immune checkpoint inhibitors in patients with non-small cell lung cancer : a pilot studyadvanced and recurrent non-small cell lung cancerJPRN-UMIN000031095Kansai Medical University30
Not yet recruiting
Not Applicable
sefulness of FDG-PET/CT to predict the response after anti-PD-1 antibody in patients with previously treated advanced non-small cell lung cancer: a multi-institutional studyPreviously treated advanced non-small cell lung cancerJPRN-UMIN000031009Gunma University120
Recruiting
Not Applicable
sefulness of FDG-PET/CT to predict the response after nivolumab in patients with previously treated advanced non-small cell lung cancerPreviously treated advanced non-small cell lung cancerJPRN-UMIN000020814Gunma30
Unknown
Not Applicable
sefulness of FDG-PET/CT to predict the response after pembrolizumab in patients with PD-L1 positive advanced non-small cell lung canceradvanced non-small cell lung cancerJPRN-UMIN000026730Gunma University Hospital50